|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Amyloid beta (A4) Precursor Protein (APP) (pSer730) Peptide
|Synonyms||APP, APP-like, APPL, Abeta, BcDNA:GH04413, EG:65F1.5, DmelCG7727, CG7727, AAA, AD1, PN2, ABPP, APPI, CVAP, ABETA, CTFgamma, aaa, ad1, pn2, abpp, appi, cvap, abeta, MGC88882, ctfgamma|
|5 references available|
|Price||49.50 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 2 to 3 Business Days|
|Characteristics||Blocking peptide for Phospho-APP-S730 antibody ABIN389515|
|Specificity||The synthetic peptide sequence used to generate the antibody AP3026a was selected from the region of human Phospho-APP-S730. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
Background: APP is a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy).
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles|
|Restrictions||For Research Use only|
Murakami, Irie, Morimoto et al.: "Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease." in: The Journal of biological chemistry, Vol. 278, Issue 46, pp. 46179-87, 2003 (PubMed).
Lleó, Berezovska, Ramdya et al.: "Notch1 competes with the amyloid precursor protein for gamma-secretase and down-regulates presenilin-1 gene expression." in: The Journal of biological chemistry, Vol. 278, Issue 48, pp. 47370-5, 2003 (PubMed).
Kim, Kim, Lee et al.: "Amyloid beta peptide (Abeta42) activates PLC-delta1 promoter through the NF-kappaB binding site." in: Biochemical and biophysical research communications, Vol. 310, Issue 3, pp. 904-9, 2003 (PubMed).
Zhou, Su, Li et al.: "Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho." in: Science (New York, N.Y.), Vol. 302, Issue 5648, pp. 1215-7, 2003 (PubMed).
Borroni, Colciaghi, Caltagirone et al.: "Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: a 2-year follow-up study." in: Archives of neurology, Vol. 60, Issue 12, pp. 1740-4, 2003 (PubMed).